Ex Vivo Drug Susceptibility of <i>Plasmodium malariae</i> Isolates to Antimalarial Drugs in Gabon

<i>Plasmodium malariae</i> is a neglected human malaria parasite despite its global distribution and propensity for persistent, sub-microscopic infections, which are associated with a mild but significant disease burden. Artemisinin-based therapies appear to be efficacious, but the susce...

Full description

Saved in:
Bibliographic Details
Main Authors: Yudi T. Pinilla, Anton Hoffmann, Maxim Viehweg, Nathanaël Saison, Stravensky Terence Boussougou Sambe, Ange Gatien Doumba Ndalembouly, Barclaye Ngossanga, Florence Awamu, Ayola Akim Adegnika, Steffen Borrmann
Format: Article
Language:English
Published: MDPI AG 2025-05-01
Series:Pathogens
Subjects:
Online Access:https://www.mdpi.com/2076-0817/14/5/453
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849326884153720832
author Yudi T. Pinilla
Anton Hoffmann
Maxim Viehweg
Nathanaël Saison
Stravensky Terence Boussougou Sambe
Ange Gatien Doumba Ndalembouly
Barclaye Ngossanga
Florence Awamu
Ayola Akim Adegnika
Steffen Borrmann
author_facet Yudi T. Pinilla
Anton Hoffmann
Maxim Viehweg
Nathanaël Saison
Stravensky Terence Boussougou Sambe
Ange Gatien Doumba Ndalembouly
Barclaye Ngossanga
Florence Awamu
Ayola Akim Adegnika
Steffen Borrmann
author_sort Yudi T. Pinilla
collection DOAJ
description <i>Plasmodium malariae</i> is a neglected human malaria parasite despite its global distribution and propensity for persistent, sub-microscopic infections, which are associated with a mild but significant disease burden. Artemisinin-based therapies appear to be efficacious, but the susceptibility profiles of field isolates are largely unknown. We performed ex vivo assays with isolates collected from asymptomatic volunteers in Gabon. The mean concentrations required to inhibit 50% of growth (IC50) with chloroquine (n = 21), artesunate (n = 20), atovaquone (n = 21), and lumefantrine (n = 14) were 7.2 nM, 2.7 nM, 3.1 nM, and 7.4 nM, respectively. Our study provides novel data on the ex vivo susceptibility of <i>P. malariae</i> to several key antimalarials, including the first dataset for atovaquone.
format Article
id doaj-art-d8133eea9ede4d2f951c3d2dca660cc4
institution Kabale University
issn 2076-0817
language English
publishDate 2025-05-01
publisher MDPI AG
record_format Article
series Pathogens
spelling doaj-art-d8133eea9ede4d2f951c3d2dca660cc42025-08-20T03:48:02ZengMDPI AGPathogens2076-08172025-05-0114545310.3390/pathogens14050453Ex Vivo Drug Susceptibility of <i>Plasmodium malariae</i> Isolates to Antimalarial Drugs in GabonYudi T. Pinilla0Anton Hoffmann1Maxim Viehweg2Nathanaël Saison3Stravensky Terence Boussougou Sambe4Ange Gatien Doumba Ndalembouly5Barclaye Ngossanga6Florence Awamu7Ayola Akim Adegnika8Steffen Borrmann9Centre de Recherches Médicales de Lambaréné, Lambaréné BP 242, GabonCentre de Recherches Médicales de Lambaréné, Lambaréné BP 242, GabonCentre de Recherches Médicales de Lambaréné, Lambaréné BP 242, GabonCentre de Recherches Médicales de Lambaréné, Lambaréné BP 242, GabonCentre de Recherches Médicales de Lambaréné, Lambaréné BP 242, GabonCentre de Recherches Médicales de Lambaréné, Lambaréné BP 242, GabonCentre de Recherches Médicales de Lambaréné, Lambaréné BP 242, GabonCentre de Recherches Médicales de Lambaréné, Lambaréné BP 242, GabonCentre de Recherches Médicales de Lambaréné, Lambaréné BP 242, GabonCentre de Recherches Médicales de Lambaréné, Lambaréné BP 242, Gabon<i>Plasmodium malariae</i> is a neglected human malaria parasite despite its global distribution and propensity for persistent, sub-microscopic infections, which are associated with a mild but significant disease burden. Artemisinin-based therapies appear to be efficacious, but the susceptibility profiles of field isolates are largely unknown. We performed ex vivo assays with isolates collected from asymptomatic volunteers in Gabon. The mean concentrations required to inhibit 50% of growth (IC50) with chloroquine (n = 21), artesunate (n = 20), atovaquone (n = 21), and lumefantrine (n = 14) were 7.2 nM, 2.7 nM, 3.1 nM, and 7.4 nM, respectively. Our study provides novel data on the ex vivo susceptibility of <i>P. malariae</i> to several key antimalarials, including the first dataset for atovaquone.https://www.mdpi.com/2076-0817/14/5/453<i>P. malariae</i>drug susceptibility assaymalariaGabon
spellingShingle Yudi T. Pinilla
Anton Hoffmann
Maxim Viehweg
Nathanaël Saison
Stravensky Terence Boussougou Sambe
Ange Gatien Doumba Ndalembouly
Barclaye Ngossanga
Florence Awamu
Ayola Akim Adegnika
Steffen Borrmann
Ex Vivo Drug Susceptibility of <i>Plasmodium malariae</i> Isolates to Antimalarial Drugs in Gabon
Pathogens
<i>P. malariae</i>
drug susceptibility assay
malaria
Gabon
title Ex Vivo Drug Susceptibility of <i>Plasmodium malariae</i> Isolates to Antimalarial Drugs in Gabon
title_full Ex Vivo Drug Susceptibility of <i>Plasmodium malariae</i> Isolates to Antimalarial Drugs in Gabon
title_fullStr Ex Vivo Drug Susceptibility of <i>Plasmodium malariae</i> Isolates to Antimalarial Drugs in Gabon
title_full_unstemmed Ex Vivo Drug Susceptibility of <i>Plasmodium malariae</i> Isolates to Antimalarial Drugs in Gabon
title_short Ex Vivo Drug Susceptibility of <i>Plasmodium malariae</i> Isolates to Antimalarial Drugs in Gabon
title_sort ex vivo drug susceptibility of i plasmodium malariae i isolates to antimalarial drugs in gabon
topic <i>P. malariae</i>
drug susceptibility assay
malaria
Gabon
url https://www.mdpi.com/2076-0817/14/5/453
work_keys_str_mv AT yuditpinilla exvivodrugsusceptibilityofiplasmodiummalariaeiisolatestoantimalarialdrugsingabon
AT antonhoffmann exvivodrugsusceptibilityofiplasmodiummalariaeiisolatestoantimalarialdrugsingabon
AT maximviehweg exvivodrugsusceptibilityofiplasmodiummalariaeiisolatestoantimalarialdrugsingabon
AT nathanaelsaison exvivodrugsusceptibilityofiplasmodiummalariaeiisolatestoantimalarialdrugsingabon
AT stravenskyterenceboussougousambe exvivodrugsusceptibilityofiplasmodiummalariaeiisolatestoantimalarialdrugsingabon
AT angegatiendoumbandalembouly exvivodrugsusceptibilityofiplasmodiummalariaeiisolatestoantimalarialdrugsingabon
AT barclayengossanga exvivodrugsusceptibilityofiplasmodiummalariaeiisolatestoantimalarialdrugsingabon
AT florenceawamu exvivodrugsusceptibilityofiplasmodiummalariaeiisolatestoantimalarialdrugsingabon
AT ayolaakimadegnika exvivodrugsusceptibilityofiplasmodiummalariaeiisolatestoantimalarialdrugsingabon
AT steffenborrmann exvivodrugsusceptibilityofiplasmodiummalariaeiisolatestoantimalarialdrugsingabon